The purpose of this study is to see if giving growth hormone or insulin-like growth factor-1 (IGF-1) to subjects with growth hormone deficiency effects cardiovascular risk factors differently.
Insulin-like growth factor-1 (IGF-1) in some circumstances acts as the mediator of the metabolic effects of growth hormone. However, there is some evidence to suggest that growth hormone (GH) and IGF-1 act differently in some metabolic pathways. We will study the differences between GH and IGF-1 when provided as therapy for growth hormone deficiency in adults. Specifically we will be assessing if either medication impacts cardiovascular risk factors and if so do they impact risk factors differently. Ten adult males ages 18-65 who are growth hormone deficient on stable medications and with stable magnetic resonance imaging (MRI) findings (in the event of a known pituitary mass) will be recruited for the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
5
300 mcg sc qd (which may be increased to 400 mcg sc qd after 4 weeks)
30 µg/kg for first 4 weeks (may be increased thereafter based on IGF-1 levels)
Columbia University, College of Physicians and Surgeons
New York, New York, United States
Cardiovascular Serum Risk Markers Including Lipids, IL-6, CRP and Homocysteine
Time frame: 2 months
Changes in Visceral Adiposity, Intrahepatic and Intramyocellular Lipids
Time frame: 2 months
Changes in Endothelial Cell Function
Time frame: 2 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.